Search

Your search keyword '"Alderuccio, Juan Pablo"' showing total 341 results
Start Over Author "Alderuccio, Juan Pablo"
341 results on '"Alderuccio, Juan Pablo"'

51. Poster: ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Kahl, Brad S., primary, Hamadani, Mehdi, additional, Caimi, Paolo F., additional, Carlo-Stella, Carmelo, additional, Ai, Weiyun, additional, Alderuccio, Juan Pablo, additional, Ardeshna, Kirit M., additional, Hess, Brian, additional, Radford, John, additional, Solh, Melhem, additional, Stathis, Anastasios, additional, Feingold, Jay, additional, Ungar, David, additional, Qin, Yajuan, additional, He, Shui, additional, and Zinzani, Pier Luigi, additional

Published
2021
Full Text
View/download PDF

54. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma

Author

Alderuccio, Juan Pablo, primary, Kuker, Russ A., additional, Barreto-Coelho, Priscila, additional, Martinez, Bianca M., additional, Miao, Feng, additional, Kwon, Deukwoo, additional, Beitinjaneh, Amer, additional, Wang, Trent P., additional, Reis, Isildinha M., additional, Lossos, Izidore S., additional, and Moskowitz, Craig H., additional

Published
2021
Full Text
View/download PDF

55. EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features

Author

Chapman, Jennifer R., primary, Bouska, Alyssa C., additional, Zhang, Weiwei, additional, Alderuccio, Juan Pablo, additional, Lossos, Izidore S., additional, Rimsza, Lisa M., additional, Maguire, Alanna, additional, Yi, Shuhua, additional, Chan, Wing C., additional, Vega, Francisco, additional, and Song, Joo Y., additional

Published
2021
Full Text
View/download PDF

57. PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Author

Alderuccio, Juan Pablo, Stanchina, Michele D., Koff, Jean L., Reis, Isildinha M., Edelman Saul, Eduardo, Larson, Melissa C., Chihara, Dai, Zhao, Wei, Habermann, Thomas M., Martin, Peter, Nastoupil, Loretta J., Chapman-Fredricks, Jennifer R., Feldman, Andrew L., Link, Brian K., Kahl, Brad S., Cohen, Jonathon B., Polar, Mark K, Henneman Sassi, Rafael, Moskowitz, Craig H., Friedberg, Jonathan W., Cerhan, James R., Kuker, Russ, Flowers, Christopher R., and Lossos, Izidore S.

Published
2023
Full Text
View/download PDF

58. Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Author

Alderuccio, Juan Pablo, Alencar, Alvaro J., Schatz, Jonathan H., Kuker, Russ, Pongas, Georgio, Reis, Isildinha M., Spiegel, Jay Y., Medina Andara, Laura, Lekakis, Lazaros J., Gyedu, Joseph S., Sandoval-Sus, Jose, Beitinjaneh, Amer M., Padron, Nathalie, Lossos, Izidore S., Rosenblatt, Joseph D., Lessen, David S., and Moskowitz, Craig H.

Published
2023
Full Text
View/download PDF

61. A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Author

Avivi Mazza, Irit, Barba, Pere, Yuda, Junichiro, Palomba, Maria Lia, Alderuccio, Juan Pablo, De Vriendt, Ciel, Corradini, Paolo, Inng Lim, Francesca Lorraine Wei, Zinzani, Pier Luigi, Jain, Nitin, Leonard, Jessica T., Coulson, Michelle, Hassounah, Nadia, Yang, Xiaoling, Lu, Haihui, Lewandowski, Andrew, Polli, Joseph Ryan, Klopfenstein, Matthieu, Pastore, Alessandro, and Brisou, Gabriel

Published
2023
Full Text
View/download PDF

63. A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Author

Iyer, Swami P., Huen, Auris, Haverkos, Bradley, Ai, Weiyun Z., Okada, Craig, Kuzel, Timothy M., Lechowicz, Mary Jo, Alderuccio, Juan Pablo, Mohrbacher, Ann, Stevens, Don A., Wilcox, Ryan A., Feldman, Tatyana A., Sundaram, Suchitra, Jagadeesh, Deepa, Reddy, Nishitha, Routhu, Kasi Viswanath, Barde, Prajak, and Nair, Ajit Mohanchandran

Published
2020
Full Text
View/download PDF

64. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime

Author

Alderuccio, Juan Pablo, Kuker, Russ A., Yang, Fei, and Moskowitz, Craig H.

Abstract

The use of functional quantitative biomarkers extracted from routine PET–CT scans to characterize clinical responses in patients with lymphoma is gaining increased attention, and these biomarkers can outperform established clinical risk factors. Total metabolic tumour volume enables individualized estimation of survival outcomes in patients with lymphoma and has shown the potential to predict response to therapy suitable for  risk-adapted treatment approaches in clinical trials. The deployment of machine learning tools in molecular imaging research can assist in recognizing complex patterns and, with image classification, in tumour identification and segmentation of data from PET–CT scans. Initial studies using fully automated approaches to calculate metabolic tumour volume and other PET-based biomarkers have demonstrated appropriate correlation with calculations from experts, warranting further testing in large-scale studies. The extraction of computer-based quantitative tumour characterization through radiomics can provide a comprehensive view of phenotypic heterogeneity that better captures the molecular and functional features of the disease. Additionally, radiomics can be integrated with genomic data to provide more accurate prognostic information. Further improvements in PET-based biomarkers are imminent, although their incorporation into clinical decision-making currently has methodological shortcomings that need to be addressed with confirmatory prospective validation in selected patient populations. In this Review, we discuss the current knowledge, challenges and opportunities in the integration of quantitative PET-based biomarkers in clinical trials and the routine management of patients with lymphoma.

Published
2023
Full Text
View/download PDF

66. Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.

Author

Caimi, Paolo, primary, Ai, Weiyun Z., additional, Alderuccio, Juan Pablo, additional, Ardeshna, Kirit, additional, Hamadani, Mehdi, additional, Hess, Brian T., additional, Kahl, Brad S., additional, Radford, John A., additional, Solh, Melhem M., additional, Stathis, Anastasios, additional, Zinzani, Pier Luigi, additional, Feingold, Jay Marshall, additional, Ungar, David, additional, Qin, Yajuan, additional, He, Shui, additional, and Carlo-Stella, Carmelo, additional

Published
2021
Full Text
View/download PDF

70. Marginal zone lymphoma of the colon: case series from a single center and SEER data review.

Author

Trabolsi, Asaad, Alderuccio, Juan Pablo, Florindez, Jorge, Rodriguez, Gregor, Saul, Eduardo, Iyer, Sunil Girish, Chapman, Jennifer R., Poveda, Julio, Sussman, Daniel A., and Lossos, Izidore S.

Subjects
*MUCOSA-associated lymphoid tissue lymphoma, *COLON (Anatomy), *SERVER farms (Computer network management), *WATCHFUL waiting, *OVERALL survival, *DIVERTICULOSIS
Abstract

Colon extranodal marginal zone lymphoma (EMZL) is poorly characterized in the literature. We performed a retrospective review of patients with colon EMZL at our institution and from the Surveillance Epidemiology and End Results (SEER) database. Eight patients were identified in our institution with majority (88%) presenting with stage-I disease. Initial management included active surveillance, polypectomy followed by surveillance, and surgical resection followed by chemotherapy. One patient with concurrent prostate carcinoma received radiation to the rectum. Initial therapy led to complete remission in five out of six treated patients with four of them maintaining remission at 88 months. SEER database identified 361 patients with stage-I colon EMZL. Overall survival for this cohort was 73.9% at 10 years with no significant difference in outcomes between treatment groups. Our single institution experience and the SEER data analysis emphasize indolent nature of colon EMZL and need for non-aggressive therapeutic approaches. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

71. A single-center analysis of patients with extranodal marginal zone lymphoma of the breast.

Author

Iyer, Sunil Girish, Kuker, Russ, Florindez, Jorge A., Saul, Eduardo, Trabolsi, Asaad, Rodriguez, Gregor, Chapman, Jennifer R., Lossos, Izidore S., and Alderuccio, Juan Pablo

Subjects
MUCOSA-associated lymphoid tissue lymphoma, PROGRESSION-free survival, BONE marrow, OVERALL survival
Abstract

Breast extranodal marginal zone lymphoma (EMZL) is a rare malignancy. We performed the largest published to date single-center retrospective analysis of 13 patients with breast EMZL focusing on clinical characteristics and treatment-related outcomes. The rarity of this disease at our center was concordant with the prevalence reported in the literature, with breast EMZL comprising 2% of 654 MZL cases. Most patients presented with stage I-II disease however four (30.8%) patients had stage IV disease mostly due to occult bone marrow (BM) involvement. Interestingly, EMZL was frequently non-FDG avid (66.7%) on staging PET/CT. With a median follow-up of 3.1 years (range 5 months to 10.2 years), the 3-year progression free survival was 68.7% (95%CI 30.2%–88.9%) and overall survival 80.2% (95%CI 40.3%-94.8%). No patient experienced higher-grade transformation. Herein we show that localized breast EMZL can be effectively treated with radiation therapy providing long term disease control. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

72. Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

Author

Alderuccio, Juan Pablo, primary, Beaven, Anne W., additional, Shouse, Geoffrey, additional, Epperla, Narendranath, additional, Stefanovic, Alexandra, additional, Torka, Pallawi, additional, Castillo, Jorge J., additional, Argnani, Lisa, additional, Voorhees, Timothy J, additional, Alpert, Ash B, additional, Chowdhury, Sayan, additional, Reis, Isildinha M., additional, Zhao, Wei, additional, Edwards, Dali, additional, Martin, Peter, additional, Kamdar, Manali, additional, Herrera, Alex F., additional, Friedberg, Jonathan W., additional, Zinzani, Pier Luigi, additional, and Lossos, Izidore S., additional

Published
2020
Full Text
View/download PDF

73. Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Author

Hess, Brian T., primary, Giri, Anshu, additional, Park, Yeonhee, additional, Patel, Krina K., additional, Link, Brian K., additional, Nowakowski, Grzegorz S., additional, Maliske, Seth M, additional, Fortin, Sonia, additional, Chavez, Julio C., additional, Saeed, Hayder, additional, Hill, Brian T., additional, Mejia Garcia, Alex V., additional, Maddocks, Kami J., additional, Hanel, Walter, additional, Wagner-Johnston, Nina D., additional, Messmer, Marcus Raymond, additional, Kahl, Brad S., additional, Watkins, Marcus, additional, Alderuccio, Juan Pablo, additional, Lossos, Izidore S., additional, Nathan, Sunita, additional, Orellana-Noia, Victor M., additional, Portell, Craig A., additional, Landsburg, Daniel J., additional, Ayers, Emily C., additional, and Castillo, Jorge J., additional

Published
2020
Full Text
View/download PDF

74. Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Author

Alderuccio, Juan Pablo, primary, Olszewski, Adam J, additional, Evens, Andrew M., additional, Collins, Graham P., additional, Danilov, Alexey, additional, Bower, Mark, additional, Jagadeesh, Deepa, additional, Zhu, Catherine, additional, Sperling, Amy, additional, Kim, Seo-Hyun, additional, Vaca, Ryan, additional, Wei, Catherine, additional, Sundaram, Suchitra, additional, Reddy, Nishitha, additional, Dalla Pria, Alessia, additional, D'Angelo, Christopher, additional, Farooq, Umar, additional, Bond, David A., additional, Berg, Stephanie, additional, Churnetski, Michael C., additional, Godara, Amandeep, additional, Khan, Nadia, additional, Choi, Yun Kyong, additional, Kassam, Shireen, additional, Yazdy, Maryam Sarraf, additional, Rabinovich, Emma, additional, Post, Frank, additional, Varma, Gaurav, additional, Karmali, Reem, additional, Burkart, Madelyn, additional, Martin, Peter, additional, Ren, Albert, additional, Chauhan, Ayushi, additional, Diefenbach, Catherine, additional, Straker-Edwards, Allandria, additional, Klein, Andreas, additional, Blum, Kristie A., additional, Boughan, Kirsten M, additional, Mian, Agrima, additional, Haverkos, Bradley, additional, Orellana-Noia, Victor M., additional, Kenkre, Vaishalee P., additional, Zayac, Adam, additional, Maliske, Seth M, additional, Epperla, Narendranath, additional, Caimi, Paolo F, additional, Smith, Scott E., additional, Kamdar, Manali, additional, Venugopal, Parameswaran, additional, Feldman, Tatyana A., additional, Rector, Daniel, additional, Smith, Stephen D., additional, Stadnik, Andrzej, additional, Portell, Craig A., additional, Lin, Yong, additional, Naik, Seema, additional, Montoto, Silvia, additional, Lossos, Izidore S., additional, and Cwynarski, Kate, additional

Published
2020
Full Text
View/download PDF

75. Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis

Author

Alderuccio, Juan Pablo, primary, Kuker, Russ A, additional, Barreto-Coelho, Priscila, additional, Martinez, Bianca Marie, additional, Miao, Feng, additional, Beitinjaneh, Amer, additional, Wang, Trent Peng, additional, Reis, Isildinha M, additional, Lossos, Izidore S., additional, and Moskowitz, Craig H., additional

Published
2020
Full Text
View/download PDF

81. NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy.

Author

Alderuccio, Juan Pablo and Lossos, Izidore S.

Subjects
*MUCOSA-associated lymphoid tissue lymphoma, *PATHOGENESIS, *DIAGNOSIS
Abstract

NOTCH signaling is a highly conserved pathway mediated by four receptors (NOTCH 1–4) playing critical functions in proliferation, differentiation, and cell death. Under physiologic circumstances, NOTCH2 is a key regulator in marginal zone differentiation and development. Over the last decade, growing data demonstrated frequent NOTCH2 mutations in splenic marginal zone lymphoma (SMZL) underscoring its critical role in the pathogenesis of this disease. Moreover, NOTCH2 specificity across studies supports the rationale to assess its value as a diagnosis biomarker in a disease without pathognomonic features. These data make NOTCH signaling an appealing target for drug discovery in SMZL; however, prior efforts attempting to manipulate this pathway failed to demonstrate meaningful clinical benefit, or their safety profile prevented further development. In this review, we discuss the current knowledge of NOTCH implications in the pathogenesis and as a potential druggable target in SMZL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

82. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.

Author

Alderuccio, Juan Pablo, Kuker, Russ A., Barreto-Coelho, Priscila, Martinez, Bianca M., Miao, Feng, Kwon, Deukwoo, Beitinjaneh, Amer, Wang, Trent P., Reis, Isildinha M., Lossos, Izidore S., and Moskowitz, Craig H.

Subjects
*DIFFUSE large B-cell lymphomas, *PROGNOSIS, *PROGRESSION-free survival, *OVERALL survival
Abstract

Identification of new prognostic factors in relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) is essential for developing risk-adapted approaches. We retrospectively analyzed prognostication based on metabolic tumor volume (MTV) in rel/ref DLBCL (n = 108) before platinum-based salvage chemotherapy. Using 41% SUVmax threshold, patients achieving complete response (CR) exhibited significantly lower baseline values of MTV, compared to those achieving partial response (PR) or with progression of disease (medians MTV 16.26 versus 72.51 versus 98.11 ml, respectively). As a continuous variable, log2(MTV) was predictive of failure to achieve CR (1-unit increase odds ratio [OR] = 1.58, p < 0.001). Log2(MTV) significantly predicted progression-free survival (PFS) and overall survival (OS), and one-unit increase in log2(MTV) was associated with shorter PFS (hazard ratio [HR] = 1.12, p = 0.035) and OS (HR = 1.17, p = 0.007). However, heterogeneity in the selection of post-salvage chemotherapy approaches may have affected survival. These data demonstrate the ability of presalvage MTV to discriminate responders from non-responders to platinum-based chemotherapy and predict survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

83. Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M, additional, Habermann, Thomas M., additional, Link, Brian K., additional, Thieblemont, Catherine, additional, Conconi, Annarita, additional, Larson, Melissa C, additional, Cascione, Luciano, additional, Zhao, Wei, additional, Cerhan, James R., additional, Zucca, Emanuele, additional, and Lossos, Izidore S., additional

Published
2019
Full Text
View/download PDF

86. Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Author

Zayac, Adam, primary, Evens, Andrew Matthew, primary, Stadnik, Andrzej, primary, Smith, Stephen D., primary, Jagadeesh, Deepa, primary, Leslie, Lori A., primary, Wei, Catherine, primary, Kim, Seo-Hyun, primary, Naik, Seema, primary, Sundaram, Suchitra, primary, Reddy, Nishitha, primary, Farooq, Umar, primary, Kenkre, Vaishalee P., primary, Epperla, Narendranath, primary, Blum, Kristie A., primary, Khan, Nadia, primary, Singh, Daulath, primary, Alderuccio, Juan Pablo, primary, Godara, Amandeep, primary, Yazdy, Maryam, primary, Diefenbach, Catherine, primary, Rabinovich, Emma, primary, Varma, Gaurav, primary, Karmali, Reem, primary, Shao, Yusra, primary, Trabolsi, Asaad, primary, Burkart, Madelyn, primary, Martin, Peter, primary, Stettner, Sarah, primary, Chauhan, Ayushi, primary, Choi, Yun Kyong, primary, Straker-Edwards, Allandria, primary, Klein, Andreas, primary, Churnetski, Michael C., primary, Boughan, Kirsten M, primary, Berg, Stephanie, primary, Haverkos, Brad M., primary, Orellana-Noia, Victor M., primary, D'Angelo, Christopher, primary, Bond, David A., primary, Maliske, Seth M, primary, Vaca, Ryan, primary, Magarelli, Gabriela, primary, Sperling, Amy, primary, Gordon, Max J., primary, David, Kevin A., primary, Caimi, Paolo, primary, Kamdar, Manali, primary, Portell, Craig A., primary, Venugopal, Parameswaran, primary, Lossos, Izidore S., primary, and Olszewski, Adam J, primary

Published
2019
Full Text
View/download PDF

88. The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Author

Evens, Andrew M., primary, Danilov, Alexey, primary, Jagadeesh, Deepa, primary, Sperling, Amy, primary, Kim, Seo-Hyun, primary, Vaca, Ryan, primary, Wei, Catherine, primary, Rector, Daniel, primary, Sundaram, Suchitra, primary, Reddy, Nishitha, primary, Lin, Yong, primary, Farooq, Umar, primary, D'Angelo, Christopher, primary, Bond, David A., primary, Berg, Stephanie, primary, Churnetski, Michael C., primary, Godara, Amandeep, primary, Khan, Nadia, primary, Choi, Yun Kyong, primary, Yazdy, Maryam, primary, Rabinovich, Emma, primary, Varma, Gaurav, primary, Karmali, Reem, primary, Mian, Agrima, primary, Ramdial, Jeremy, primary, Burkart, Madelyn, primary, Martin, Peter, primary, Ren, Albert, primary, Chauhan, Ayushi, primary, Diefenbach, Catherine, primary, Straker-Edwards, Allandria, primary, Klein, Andreas, primary, Blum, Kristie A., primary, Boughan, Kirsten M, primary, Smith, Scott E., primary, Haverkos, Brad M., primary, Orellana-Noia, Victor M., primary, Kenkre, Vaishalee P., primary, Zayac, Adam, primary, Maliske, Seth M, primary, Epperla, Narendranath, primary, Venugopal, Parameswaran, primary, Feldman, Tatyana A., primary, Smith, Stephen D., primary, Stadnik, Andrzej, primary, Lossos, Izidore S., primary, David, Kevin A., primary, Naik, Seema, primary, Caimi, Paolo, primary, Kamdar, Manali, primary, Portell, Craig A., primary, Olszewski, Adam J, primary, and Alderuccio, Juan Pablo, primary

Published
2019
Full Text
View/download PDF

91. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

Author

Alderuccio, Juan Pablo, primary, Zhao, Wei, additional, Desai, Amrita, additional, Ramdial, Jeremy, additional, Gallastegui, Nicolas, additional, Kimble, Erik, additional, Fuente, Macarena I., additional, Husnain, Muhammad, additional, Rosenblatt, Joseph D., additional, Alencar, Alvaro J., additional, Schatz, Jonathan H., additional, Moskowitz, Craig H., additional, Chapman, Jennifer R., additional, Vega, Francisco, additional, Reis, Isildinha M., additional, and Lossos, Izidore S., additional

Published
2019
Full Text
View/download PDF

93. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

Author

Hill, Brian T., primary, Nastoupil, Loretta, additional, Winter, Allison M., additional, Becnel, Melody R., additional, Cerhan, James R., additional, Habermann, Thomas M., additional, Link, Brian K., additional, Maurer, Matthew J., additional, Fakhri, Bita, additional, Reddy, Prathima, additional, Smith, Stephen D., additional, Mukhija, Dhruvika, additional, Jagadeesh, Deepa, additional, Desai, Amrita, additional, Alderuccio, Juan Pablo, additional, Lossos, Izidore S., additional, Mehra, Pooja, additional, Portell, Craig A., additional, Goldman, Max L., additional, Calzada, Oscar, additional, Cohen, Jonathon B., additional, Hussain, Mohammad J., additional, Ghosh, Nilanjan, additional, Caimi, Paolo, additional, Tiutan, Timothy, additional, Martin, Peter, additional, Kodali, Abhigna, additional, Evens, Andrew M., additional, and Kahl, Brad S., additional

Published
2018
Full Text
View/download PDF

94. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution

Author

Alderuccio, Juan Pablo, primary, Zhao, Wei, additional, Desai, Amrita, additional, Gallastegui, Nicolas, additional, Ramdial, Jeremy, additional, Kimble, Erik, additional, de la Fuente, Macarena I., additional, Rosenblatt, Joseph D., additional, Chapman, Jennifer R., additional, Vega, Francisco, additional, Reis, Isildinha M., additional, and Lossos, Izidore S., additional

Published
2018
Full Text
View/download PDF

95. Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma.

Author

Poveda, Julio, Cassidy, Daniel P., Zhou, Yi, Alderuccio, Juan Pablo, Lossos, Izidore S., Vega, Francisco, and Chapman, Jennifer

Subjects
MUCOSA-associated lymphoid tissue lymphoma, GERMINAL centers, LYMPHOMAS, B cells, PROTEIN expression, MALT
Abstract

We reviewed 341 consecutive cases of marginal zone lymphoma (MZL) (47) or follicular lymphoma (FL) (294) of which 7 were difficult to distinguish due to perceived coexpression of BCL6 and BCL2 by tumor cells in follicular foci. This stimulated us to develop dual BCL6/BCL2 immunohistochemistry, allowing us to assess coexpression among individual cells. Dual staining confirmed coexpression in 6 of 7 cases, all extranodal MZL (ENMZL) based on overall features and representing 13% of MZL in this series. These findings confirm that MZL cells have plasticity regarding protein expression within the germinal center (GC) microenvironment, an important diagnostic pitfall. Intriguingly, in all MZL expressing BCL6, non-neoplastic GC B cells within colonized follicles showed diminished or absent CD10 expression but preserved BCL6 and high ki67. This finding suggests plasticity of CD10 expression in non-neoplastic GC B cells in the context of colonization by MZL, possibly related to NF-kB dysregulation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

96. Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma.

Author

Lossos, Izidore S., Reis, Isildinha M., Rosenblatt, Joseph D., and Alderuccio, Juan Pablo

Subjects
GRANULOCYTE-colony stimulating factor, BLOOD platelet transfusion, LYMPHOMAS, IMMUNOTHERAPY
Abstract

The best upfront therapy for patients with non-gastric extranodal marginal zone lymphoma (EMZL) remains unclear. Notably, 5 (29.4%) patients remain alive and without lymphoma relapse, with 4 (23.6%) for more than 10 years; 5 (29.4%) patients remain alive for more than 6 years after relapse within the first 3 years of diagnosis, and all 7 deaths were non-lymphoma related (Table 1). Two patients pursued with surveillance (1 asymptomatic patient and another patient with liver failure secondary to primary sclerosing cholangitis). Progression-free survival (A), overall survival (B), cumulative incidence of relapse accounting for 5 non-lymphoma death as competing risk (C), and time-to-events by patient (D) in 17 patients treated with 90Y-ibritumomab. [Extracted from the article]

Published
2020
Full Text
View/download PDF

97. Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers

Author

Hill, Brian T., Nastoupil, Loretta, Winter, Allison M., Becnel, Melody R., Cerhan, James R., Habermann, Thomas M., Link, Brian K., Maurer, Matthew J., Fakhri, Bita, Reddy, Prathima, Smith, Stephen D., Mukhija, Dhruvika, Jagadeesh, Deepa, Desai, Amrita, Alderuccio, Juan Pablo, Lossos, Izidore S., Mehra, Pooja, Portell, Craig A., Max Goldman, Calzada, Oscar, Cohen, Jonathon B., Hussain, Mohammad Junaid, Ghosh, Nilanjan, Caimi, Paolo, Tiutan, Timothy, Martin, Peter, Kodali, Abhigna, Evens, Andrew M., and Kahl, Brad S.

Published
2017
Full Text
View/download PDF

98. Central nervous system emergencies in haematological malignancies.

Author

Fuente, Macarena I., Alderuccio, Juan Pablo, and Lossos, Izidore S.

Subjects
*CENTRAL nervous system, *INTRACRANIAL hypertension, *SPINAL cord compression, *NEUROLOGICAL emergencies, *STATUS epilepticus
Abstract

Summary: Neurological emergencies are frequently catastrophic events in the course of haematological malignancies (HM) that, if not promptly recognized and treated, may lead to lethal outcomes or chronic sequelae. They may occur at any time during the disease course, but are more frequently observed following relapse. Practice guidelines are lacking in the management of most central nervous system (CNS) complications in HM. Herein we review the pathophysiology, presentation and treatment of elevated intracranial pressure, spinal cord compression, status epilepticus, neurovascular complications, CNS infection, leucostasis and hyperviscosity. Further, we discuss the expanding spectrum of neurological complications of old and novel treatments in HM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

99. Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Author

Winter, Allison M., primary, Nastoupil, Loretta J., additional, Becnel, Melody R., additional, Cerhan, James R., additional, Habermann, Thomas M., additional, Link, Brian K., additional, Maurer, Matthew J., additional, Fakhri, Bita, additional, Reddy, Prathima, additional, Smith, Stephen D., additional, Mukhija, Dhruvika, additional, Jagadeesh, Deepa, additional, Desai, Amrita, additional, Alderuccio, Juan Pablo, additional, Lossos, Izidore S., additional, Mehra, Pooja, additional, Portell, Craig A., additional, D'Angelo, Christopher R., additional, Kenkre, Vaishalee P., additional, Goldman, Max L., additional, Calzada, Oscar, additional, Cohen, Jonathon B., additional, Hussain, Mohammad Junaid, additional, Ghosh, Nilanjan, additional, Liu, Yang, additional, Barta, Stefan Klaus, additional, Caimi, Paolo F, additional, Kittai, Adam, additional, Danilov, Alexey V, additional, Tiutan, Timothy, additional, Martin, Peter, additional, Danielson, Nathalie, additional, Kamdar, Manali, additional, Kodali, Abhigna, additional, Evens, Andrew M., additional, Kahl, Brad S, additional, and Hill, Brian T., additional

Published
2018
Full Text
View/download PDF

100. Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology

Author

Qu, Changju, primary, Kunkalla, Kranthi, additional, Vaghefi, Amineh, additional, Frederiksen, John K., additional, Liu, Yadong, additional, Chapman, Jennifer R., additional, Blonska, Marzenna, additional, Bernal-Mizrachi, Leon, additional, Alderuccio, Juan Pablo, additional, Lossos, Izidore S., additional, Landgraf, Ralf, additional, and Vega, Francisco, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results